- ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)Solomon, B. J.; Ahn, J. S.; Dziadziuszko, R.; Barlesi, F.; Nishio, M.; Lee, D. H.; Lee, J. S.; Zhong, W. Z.; Horinouchi, H.; Mao, W.; Hochmair, M. J.; De Marinis, F.; Migliorino, M. R.; Bondarenko, I.; Lohmann, T. O.; Xu, T.; Gavaldon, A. Cardona; Bordogna, W.; Ruf, T.; Wu, Y. L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.被引 3
- Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trialYang, Yunpeng; Min, Jie; Yang, Nong; Yu, Qitao; Cheng, Ying; Zhao, Yanqiu; Li, Manxiang; Chen, Hong; Ren, Shouan; Zhou, Jianying; Zhuang, Wu; Qin, Xintian; Cao, Lejie; Yu, Yan; Zhang, Jian; He, Jianxing; Feng, Jifeng; Yu, Hao; Zhang, Li*; Fang, Wenfeng*Signal Transduction and Targeted Therapy, 2023, 8(1): 301.
- Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK plus non-small cell lung cancer (NSCLC): A sub analysis of ALINAAhn, J. S.; Wu, Y-L.; Dziadziuszko, R.; Barlesi, F.; Nishio, M.; Lee, D. H.; Lee, J-S.; Zhong, W-Z.; Horinouchi, H.; Mao, W.; Lu, S.; Wang, Q.; Yang, C-T.; Korphaisarn, K.; Xu, T.; Bu, L.; Scalori, A.; Petric, P.; Redhead, K.; Solomon, B.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
Envonalkib vs crizotinib in treatment-naive advanced ALKpositive NSCLC: A randomized, multicenter, phase III trial
1被引18阅读
